Effects of Regular Follow-up on Quality of Life and Warfarin Efficiency in Rural Patients

Salih Kılıç; Erhan Saraçoğlu; Yusuf Çekici; Dilara Deniz Kılıç; Arafat Yıldırım; Zülfiye Kuzu

doi:10.5152/EurJTher.2018.602

Authors

Salih Kılıç Clinic of Cardiology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep https://orcid.org/0000-0002-3579-3747
Erhan Saraçoğlu Clinic of Cardiology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep https://orcid.org/0000-0002-4585-3707
Yusuf Çekici Clinic of Cardiology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep https://orcid.org/0000-0002-4585-3707
Dilara Deniz Kılıç Clinic of Internal Medicine, Nizip State Hospital, Gaziantep https://orcid.org/0000-0002-3699-2158
Arafat Yıldırım Clinic of Cardiology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep https://orcid.org/0000-0002-2798-7488
Zülfiye Kuzu Clinic of Cardiology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep https://orcid.org/0000-0001-5378-5516

DOI:

https://doi.org/10.5152/EurJTher.2018.602

Keywords:

Duke Anticoagulation Satisfaction Scale, health-related quality of life, warfarin therapy

Abstract

Objective: This study aims to evaluate the effects of regular follow-up and education on warfarin efficiency, satisfaction, and the quality of life in patients from rural areas.
Methods: A total of 133 patients from rural areas taking warfarin were followed up for the mean of 17.4±0.5 months (mean age 58±13 years, 72.9% female). All patients were educated and followed up by a single cardiologist prospectively. A list and an illustrated booklet presenting foods that interact with warfarin and a follow-up chart were prepared for each patient. An illustrated scheme of pills that were to be taken every day was prepared for illiterate patients. The international normalized ratio (INR) values during and 1 year before the study were recorded from the hospital system, and the time in therapeutic range (TTR) was calculated. The Duke Anticoagulation Satisfaction Scale was conducted at the start and end of the study to determine patients’ satisfaction with warfarin use. Furthermore, the Medical Outcomes Study Form 36 (SF-36) was used for determining the health-related quality of life (HRQoL).
Results: A total of 45.9% of patients were illiterate, and 33.8% were primary school graduates. The median TTR during the follow-up increased significantly compared with the previous year [40.0 (IQR 36.5) vs. 62.1 (IQR 29.3); p<0.001]. Furthermore, the number of patients with TTR>70% increased significantly (36.8% vs. 21.1%, respectively; p<0.001). Unfortunately, patients’ HRQoLnand satisfaction with warfarin use were found to have deteriorated significantly compared to the basal levels.
Conclusion: We found that the efficiency of warfarin increased significantly, but interestingly, HRQoL and the satisfaction with warfarin use deteriorated significantly after regular education and follow-up in patients from rural areas.

Metrics

Metrics Loading ...

References

Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012; 33: 2719-47.

Turk UO, Tuncer E, Alioglu E, Yuksel K, Pekel N, Ozpelit E, et al. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: Perspectives from the observational, prospective WATER Registry. Cardiol J 2015; 22: 567-75.

Ertaş F, Kaya H, Kaya Z, Bulur S, Köse N, Gül M, et al. Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. Turk Kardiyol Dern Ars 2013; 41: 99-104.

Çelik A, İzci S, Kobat MA, Ateş AH, Çakmak A, Çakıllı Y, et al. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardioln2016;16:595-600.

Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients’ warfarin knowledge and anticoagulation control. Ann Pharmacother 2003; 37: 34-9.

Casais P, Meschengieser S, Sanchez-Luceros A, Lazzari M. Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life. Curr Med Res Opin 2005; 21: 1085-90.

Samsa G, Matchar DB, Dolor RJ, Wiklund I, Hedner E, Wygant G, et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes 2004; 2: 22.

Tokgözoğlu L, Oğuz A, Balcı MK, Temizhan A, Altunoğlu EG, Bektaş O, et al. Turkish assessment of SURF (SUrvey of Risk Factor Management) study: Control rates of cardiovascular risk factors derived from databases of 15 different levels of health centers in Turkey. Turk Kardiyol Dern Ars 2017; 45: 398-407.

Rosendaal F, Cannegieter S, van der Meer F, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.

Samsa G, Matchar DB, Dolor RJ, Wiklund I, Hedner E, Wygant G, et al. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes 2004; 2: 22.

Stewart AL, Hays RD, Ware JE Jr. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988; 26: 724-35.

Yıldırım JG, Temel AB. Duke antikoagülan memnuniyet ölçeğinin Türkçe formunun geçerlik ve güvenirliği. Turk Gogus Kalp Dama 2014; 22: 761-72.

Koçyiğit H, Aydemir Ö, Fişek G, Ölmez N, Memiş A. Kısa Form-36 (KF36)’nın Türkçe versiyonunun güvenilirliği ve geçerliliği. İlaç Tedavi Derg 1999; 12: 102-6.

Kılıç S, Çelik A, Çakmak HA, Afşin A, Tekkeşin Aİ, Açıksarı G, et al. The time in therapeutic range and bleeding complications of warfarin in different geographic regions of Turkey: a subgroup analysis of WARFARIN-TR Study. Balkan Med J 2017; 34: 349-55.

Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11: ix-66.

Heneghan C, Alonso-Coello P, Garcia-Alamino J, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367: 404-11.

Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, et al. Self-monitoring and self-management of oral anticoagulation. Sao Paulo Med J 2010; 128: 246.

Kılıç S, Soner Kemal H, Yüce Eİ, Şimşek E, Yağmur B, Memişoğlu Akgül N, et al. Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. Anatol J Cardiol 2017; 18: 328-33.

Ansell J, Jacobson A, Levy J, Völler H, Hasenkam JM; InternationalSelf-Monitoring Association for Oral Anticoagulation. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol 2005; 99: 37-45.

Prins MH, Marrel A, Carita P, Anderson D, Bousser MG, Crijns H, et al. Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the ‘Perception of Anticoagulant Treatment Questionnaire’ (PACT-Q). Health Qual life Outcomes 2009; 7: 9.

Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients’ perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract 2004; 5: 15.

Carris NW, Hwang AY, Smith SM, Taylor JR, Sando K, Powell J, et al. Patient satisfaction with extended-interval warfarin monitoring. J Thromb Thrombolysis 2016; 42: 486-93.

Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010; 4: 51-60.

Das AK, Ahmed A, Corrado OJ, West RM. Quality of life of elderly people on warfarin for atrial fibrillation. Age Ageing 2009; 38: 751-4.

Pelegrino FM, Dantas RA, Corbi IS, da Silva Carvalho AR, Schmidt A, Pazin Filho A. Cross-cultural adaptation and psychometric properties of the Brazilian-Portuguese version of the Duke Anticoagulation Satisfaction Scale. J Clin Nurs 2012; 21: 2509-17.

Corbi IS, Dantas RA, Pelegrino FM, Carvalho AR. Health related quality of life of patients undergoing oral anticoagulation therapy. Rev Lat Am Enfermagem 2011; 19: 865-73.

Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-83.

Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331-9.

ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study. Am Heart J 2010; 159: 340-7.

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48). Am Heart J 2010; 160: 635-41.